2026. Effectiveness of Erythropoiesis-Stimulating Agent Therapy with Oral and Intravenous Iron Supplementation in Achieving Hemoglobin Targets in Stage 5 Chronic Kidney Disease Patients. JURNAL FARMASIMED (JFM). 9, 1 (Oct. 2026), 499–507. DOI:https://doi.org/10.35451/jfm.v9i1.3691.